|
|
8/23/2006 9:41:47 AM ET
SWISS MEDICA ANNOUNCES CARIBBEAN DISTRIBUTION DEAL FOR O24™
FOR IMMEDIATE RELEASE
Stock Symbol: OTC BB: SWME
August 23, 2006
Toronto, Canada – Swiss Medica, Inc. (OTC BB: SWME) announced today that the Caribbean Institute of
Orthopedics (“CIO”) has become a Swiss Medica international distribution partner. CIO, with offices in Santo
Domingo, Dominican Republic will be marketing and distributing Swiss Medica’s O24 products throughout the
Caribbean.
According to Kamille Ramsunder, the President of the Caribbean Institute of Orthopedics:
“We are officially endorsing Swiss Medica’s award winning O24™ Pain Neutralizer as our flagship pain product
for this region. CIO is hoping to fight crippling diseases like Osteoarthritis/Rheumatoid Arthritis and Fibromyalgia
in the most natural way and we have found that there is no better way to relieve chronic pain than to use Swiss
Medica’s O24™ Pain Neutralizer. Swiss Medica’s O24™ Pain Neutralizer has also been endorsed by our
partners The Canadian Institute of Orthopedics.”
Grant Johnson, President and COO of Swiss Medica stated “We are proud to see the international orthopedic
community reach out and endorse our products, and it is our goal to continue to grow Swiss Medica’s
international presence through these strategic distribution deals. We expect to make several more
announcements regarding our international expansion plans over the next several months.”
About the Caribbean Institute of Orthopedics
The Caribbean Institute of Orthopedics (CIO) supplies professional services to patients requiring orthotic
devices and specialized braces for a variety of biomechanical problems for the entire Caribbean region. The
Caribbean region compromises the islands of Bahamas, Barbados, Dominican Republic, Cuba, Aruba among
others and according the latest United Nations survey (2004) of the Caribbean, the twenty-four island nations
have a population over 38-million and a Gross Domestic Product that is growing at 2.4% a year.
About Swiss Medica, Inc.
Swiss Medica is a specialty pharmaceutical company focused on commercializing over-the-counter clinically-
tested, patented all-natural products that relieve chronic ailments. Swiss Medica builds its brands through
innovative and focused distribution and marketing strategies. Swiss Medica's mission is to be a world leader in
the commercialization of over-the-counter, safe and effective chronic ailment treatments. Please visit our
websites at www.swissmedica.com, www.O24zone.com and www.pmsescape.com.
Swiss Medica's flagship product, the O24™ Pain Neutralizer, holds US Patent #6,444,238B1. The O24™ pain
relief solution has been used and recommended for its fast-acting and long-lasting benefits by healthcare
professionals and athletes in the United States, Canada and in Europe. O24™ is widely available over-the-
counter throughout the United States and Canada in leading pharmacies and other retailers. Customers can
also visit www.O24zone.com, for ordering details and store locators for the nearest pharmacy.
Swiss Medica has recently launching the patented O24 Fibromyalgia™ pain reliever (US Patent #6,444,238B1)
over-the-counter in North American retailers. The National Fibromyalgia Association (NFA) recently awarded
O24 Fibromyalgia™ their first NFA Seal of Approval. Over 10 million Americans suffer from the long-term pain
associated with fibromyalgia. In a randomized double blind clinical trial conducted in 2005, 88 per cent of the
patients who used O24 Fibromyalgia™ reported mild to markedly better improvement, versus only 7 per cent
who used the placebo. Customers can also visit www.O24zone.com for ordering details and store locators for the
nearest retailer.
Swiss Medica also distributes PMS Escape® which holds US Patent #'s 5760014 and 5612320. PMS Escape® is
a specially formulated group of carbohydrates, vitamins and minerals, clinically proven to reduce changes in
mood and appetite that women experience during the premenstrual period. Customers can also visit:
www.pmsescape.com for additional information and ordering details.
Forward-looking statements in this news release are made pursuant to the "Safe Harbor" provisions of the
United States Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking
statements involve risks and uncertainties, including, without limitation, risks relating to the ability to close
transactions being contemplated, risks related to international sales and potential foreign currency exchange
fluctuations, continued acceptance of Swiss Medica's products, increased levels of competition, technological
changes, dependence on intellectual property rights and other risks detailed from time to time in Swiss Medica's
periodic reports filed with the United States Securities and Exchange Commission and other regulatory
authorities.
For more information, please contact:
Swiss Medica, Inc.
Investor Relations Contact:
David Jones
1-866-485-4243
djones@swissmedica.com
|
|
